Olverembatinib is a targeted therapy indicated for the treatment of specific types of leukemia. Its use in special populations must strictly adhere to the principle of individualized medication. Populations including children, pregnant women, lactating women, patients with hepatic or renal impairment, and the elderly require careful assessment of risks and benefits. During the treatment course, close monitoring for adverse reactions is essential, with timely dose adjustments or regimen modifications as needed.
I. Precautions for Medication in Special Populations
1. Pediatric and Adolescent Patients
Sufficient clinical data in patients under 18 years of age are lacking. Use should only be considered when the treating physician determines that potential benefits outweigh the risks, with rigorous monitoring of growth and development as well as drug-related toxicities.
2. Pregnant and Lactating Women
Contraindicated in pregnant women
Animal studies have demonstrated embryotoxicity, which may pose harm to the fetus. Effective contraceptive measures must be adopted during treatment. In the event of accidental pregnancy, discontinue the drug immediately and consult a physician.
Avoid use during lactation
Olverembatinib may be excreted in human milk. It is recommended to suspend breastfeeding throughout the treatment period and for at least 1 week after drug discontinuation.
3. Patients with Hepatic or Renal Impairment
Hepatic impairment
Dose adjustment is required for patients with moderate to severe hepatic dysfunction. It is recommended to reduce the initial dose by 25%–50%, with regular monitoring of liver function parameters (e.g., alanine aminotransferase [ALT], aspartate aminotransferase [AST]).
Renal impairment
Use with caution in patients with creatinine clearance (CrCl) < 30 mL/min or those receiving dialysis. Dose reduction or prolongation of the dosing interval may be necessary.
4. Geriatric Patients
Due to age-related decline in physiological functions and increased risk of comorbidities, dose adjustment should be made based on hepatic/renal function, concurrent medications, and overall health status. Enhanced monitoring for adverse reactions (e.g., infection, bleeding tendency) is also required.
II. Medication Monitoring and Risk Prevention
1. Drug Interactions
Coadministration with potent CYP3A4 inhibitors (e.g., clarithromycin) or inducers (e.g., rifampicin) may alter plasma drug concentrations, necessitating dose adjustment or avoidance of concomitant use.
Avoid coadministration with anticoagulants or antiplatelet agents, as this may increase the risk of bleeding.
2. Key Monitoring Indicators
Conduct regular tests including complete blood count (with close attention to platelet and neutrophil counts), liver function, electrocardiogram (to assess the risk of QT interval prolongation), and electrolyte levels.
Discontinue the drug immediately and seek medical attention if severe infection, bleeding, or cardiotoxicity (e.g., arrhythmia) occurs.
3. Medication Guidance
Administer the drug strictly in accordance with the physician’s instructions; do not adjust the dose or discontinue treatment without authorization. If a dose is missed, do not take a double dose; resume the original dosing schedule as planned.
Avoid vaccination with live vaccines during treatment and take precautions to prevent infection.
Note: Olverembatinib is a prescription-only medication and must be used under the supervision of a hematologist. A comprehensive baseline assessment should be completed prior to treatment initiation. Patients are advised to attend regular follow-up visits and report any adverse symptoms during the treatment period.
